BCAB
BioAtla, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+2.66%Aug 18, 2026, 16:15 UTC
Biokin Pharma announced that its bispecific ADC iza-bren met the primary endpoint in the Panku-Lung01 phase 3 lung cancer trial, showing significant progression-free survival benefit.
Source: